1 / 30

Rational Drug Design : HIV Integrase

Rational Drug Design : HIV Integrase. A process for drug design which bases the design of the drug upon the structure of its protein target. Structural mapping of the receptor (protein, P) active site Identification of ligands (L) of complementary shape and appropriate functionality

johnda
Download Presentation

Rational Drug Design : HIV Integrase

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Rational Drug Design : HIV Integrase

  2. A process for drug design which bases the design of the drug upon the structure of its protein target. Structural mapping of the receptor (protein, P) active site Identification of ligands (L) of complementary shape and appropriate functionality Docking of the ligand to the receptor site - predicting a range of PL complexes with different DGPL values 4. Scoring i.e. ranking DGPL and correlating with experimentally determined properties such as IC50 values

  3. The catalytic domainhas an RNaseH-type fold and belongs to the superfamily of polynucleotidyl transferases. The active site is comprised of two Asp residues and one Glu, in the typicalD,D(35)E motif, each of which is required for catalysis.

  4. de novo Ligand Design

  5. four criteria to conclude that integrase is theinhibitor target: 1. found to be active against recombinant integrase. 2. infected cells treated with the drug must show an accumulation of 2-LTR circles, resulting from the accumulation of viral cDNA and decreased HIV integration into host 3. integrase mutations must be found in drug-resistant viruses 4, the drug should be inactive in biochemical assays against recombinantintegrases bearing the mutations identified in the drug-resistant viruses DKAs DCQ acids; DCT acids PDP SQL Quinolone derived

  6. Issues in Protein Setup • Crystal structure available for Integrase but : I. Limitations of crystal structure: • only catalytic domain • DNA binding not revealed • cystal structure vs. physiologically active structure II. Position of hydrogens undetermined III. Residues missing or ill-defined IV. Protonation of His undetermined V. Solvation

  7. Issues in Protein Setup Crystal structure available for Integrase Catalytic Domain but : I. Crystal reveals trimeric structure II. Position of hydrogens undetermined III. Residues missing or ill-defined IV. Protonation of His undetermined V. Solvation

  8. Issues in Protein Setup Crystal structure available for Integrase Catalytic Domain but : I. Crystal reveals trimeric structure II. Position of hydrogens undetermined III. Residues missing or ill-defined IV. Protonation of His undetermined V. Solvation

  9. Issues in Protein Setup Crystal structure available for Integrase Catalytic Domain but : I. Crystal reveals trimeric structure II. Position of hydrogens undetermined III. Residues missing or ill-defined IV. Protonation of His undetermined V. Solvation

  10. Issues in Protein Setup Crystal structure available for Integrase Catalytic Domain but : I. Crystal reveals trimeric structure II. Position of hydrogens undetermined III. Residues missing or ill-defined IV. Protonation of His undetermined V. Solvation

  11. Issues in Protein Setup Crystal structure available for Integrase Catalytic Domain but : I. Crystal reveals trimeric structure II. Position of hydrogens undetermined III. Residues missing or ill-defined IV. Protonation of His undetermined V. Solvation

  12. Issues in Ligand Design Crystal structure available for CITEP bound to catalytic core but : I. Position of hydrogens undetermined II. Tautomeric structures possible III. Influence of pH IV. Need to limit conformational flexibility based on experimental and theoretical crteria

  13. Issues in Ligand Design Crystal structure available for CITEP bound to catalytic core but : I. Position of hydrogens undetermined II. Tautomeric structures possible III. Influence of pH IV. Need to limit conformational flexibility based on experimental and theoretical crteria

  14. Issues in Ligand Design Crystal structure available for CITEP bound to catalytic core but : I. Position of hydrogens undetermined II. Tautomeric structures possible III. Influence of pH IV. Need to limit conformational flexibility based on experimental and theoretical crteria

  15. Issues in Ligand Design Crystal structure available for CITEP bound to catalytic core but : I. Position of hydrogens undetermined II. Tautomeric structures possible III. Influence of pH IV. Need to limit conformational flexibility based on experimental and theoretical crteria Tetrazole pKa=5

  16. Issues in Ligand Design Crystal structure available for CITEP bound to catalytic core but : I. Position of hydrogens undetermined II. Tautomeric structures possible III. Influence of pH IV. Need to limit conformational flexibility based on experimental and theoretical crteria Fixed and planar Based on HF/6-31G* calculations Limited to +/- 45 degrees

  17. Issues in Docking The prediction of the ligand conformation and orientation within a targeted binding site involves: I. Positioning ligand and evaluating quality of binding II. Manually refining ligand position III. Energy minimization (electrostatic, steric, strain and h-bond)

  18. Issues in Docking The prediction of the ligand conformation and orientation within a targeted binding site involves: I. Positioning ligand and evaluating quality of binding II. Manually refining ligand position III. Energy minimization (electrostatic, steric, strain and h-bond)

  19. Issues in Docking The prediction of the ligand conformation and orientation within a targeted binding site involves: I. Positioning ligand and evaluating quality of binding II. Manually refining ligand position III. Energy minimization (electrostatic, steric, strain and h-bond)

  20. Issues in Scoring The prediction of the optimum ligand conformation and orientation within a targeted binding site involves: I. Posing : Determining the fit of the ligand II. Conformational Searching III. Scoring and Ranking

  21. Results

  22. Results

  23. Ligand Design Criterion for Ligand Selection: I. Theoretical and experimental structures II. Fill active site III. Conformational structures

  24. Ligand Design Criterion for Ligand Selection: I. Theoretical and experimental structures II. Fill active site III. Conformational structures

  25. Ligand Design Criterion for Ligand Selection: I. Theoretical and experimental structures II. Fill active site III. Conformational structures

  26. Site Mutations and Drug Resistance The prediction of the affects of mutations within the binding site on the effects of the ligands involves: I. Identifying possible sights of mutations II. Determining effect of mutations

  27. Site Mutations and Drug Resistance The prediction of the affects of mutations within the binding site on the effects of the ligands involves: I. Identifying possible sights of mutations II. Determining effect of mutations

  28. Site Mutations and Drug Resistance

  29. Problem with Protein Flexibility http://folding.stanford.edu/villin/S300x300.105.56.95.mpg

More Related